Latano-Vision

Latanoprost, the active ingredient in Latano-Vision, is a prostaglandin F2α analog presented as a eye drops for ocular use. It treats primary open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latano-Vision as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in several ocular conditions.

- Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma. - Pseudoexfoliative glaucoma: helps control pressure in this secondary form of open‑angle glaucoma.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Iris pigmentation: progressive darkening of the iris. - Eyelash changes: increased length, thickness or darkness. - Eye discomfort: transient stinging or burning on instillation.

Serious or Rare Side Effects: - Inflammatory eye conditions: uveitis or keratitis. - Severe allergic reaction: eyelid swelling, rash, or anaphylaxis. - Vision loss: rare cases of sudden visual acuity reduction.

Before initiating Latano-Vision, consider the following precautions.

- Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; consider potential risk to the infant. - Contraindications: known hypersensitivity to latanoprost or any excipient. - Monitoring: assess intra‑ocular pressure after initiation and periodically thereafter. - Contact lens wearers: may cause deposits; remove lenses before instillation. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents; review patient medication lists.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: may cause excessive pressure reduction leading to hypotony. - Use with topical non‑steroidal anti‑inflammatory eye drops: may diminish latanoprost efficacy.

Moderate Interactions (Monitor Closely): - Systemic carbonic anhydrase inhibitors: additive intra‑ocular pressure‑lowering effect. - Beta‑blocker eye drops: combined effect may increase pressure reduction. - Anticholinergic ophthalmic agents: may affect ocular surface tolerance.